뇌종양 치료제 시장 : 제품 유형, 치료 접근, 종양 유형, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Brain Tumor Therapeutics Market is projected to grow by USD 6.99 billion at a CAGR of 10.10% by 2032.

Brain Tumor Therapeutics Market Executive Summary

Brain tumor therapeutics are entering a more precise era as neuro-oncology shifts from histology-led treatment to molecularly defined care. The global burden remains clinically urgent: IARC GLOBOCAN 2022 reported more than 320,000 new cancers of the brain and central nervous system worldwide, while glioblastoma continues to carry a median survival of roughly 15 months with standard surgery, radiotherapy, and temozolomide-based chemotherapy.

Growth in the brain tumor therapeutics market is being shaped by IDH-targeted drugs, immuno-oncology combinations, antibody-drug conjugates, radiopharmaceutical research, tumor treating fields, and improved drug delivery across the blood-brain barrier. FDA approval of vorasidenib in 2024 for IDH-mutant grade 2 glioma strengthened confidence in biomarker-driven neuro-oncology pipelines and reinforced the strategic importance of precision medicine in brain cancer treatment.

Transformative Shifts in Brain Tumor Therapeutics

The competitive landscape is moving from broad cytotoxic treatment toward integrated regimens built around molecular profiling, maximal safe resection, advanced radiotherapy, and targeted systemic therapy. The 2021 WHO Classification of CNS Tumors made molecular markers central to diagnosis, increasing demand for next-generation sequencing, IDH testing, MGMT promoter methylation assessment, and 1p/19q codeletion analysis.

Transformative shifts also include novel trial designs, decentralized imaging review, adaptive platform studies, and greater use of real-world evidence. Because many brain tumors are rare or biologically heterogeneous, sponsors are prioritizing biomarker-enriched cohorts, companion diagnostics, and endpoints that capture progression-free survival, neurocognitive function, corticosteroid use, seizure control, and quality of life.

Cumulative Impact of Artificial Intelligence on Neuro-Oncology

Artificial intelligence is becoming a practical accelerator across the brain tumor care pathway. In radiology, AI-enabled segmentation and volumetric assessment can support more consistent MRI interpretation, tumor burden tracking, edema evaluation, and radiotherapy planning; in pathology, digital image analysis can help quantify morphology and guide molecular testing workflows.

AI is also influencing drug discovery and clinical development by supporting target prioritization, blood-brain barrier permeability modeling, patient stratification, synthetic control exploration, and trial-site selection. The highest-value applications are those validated against clinical outcomes, integrated into regulated workflows, and governed with transparent data provenance, bias monitoring, cybersecurity safeguards, and physician oversight.

Key Regional Insights Across Brain Tumor Therapeutics

North America remains a leading innovation hub for brain tumor therapeutics, supported by the U.S. National Cancer Institute, major academic cancer centers, high clinical trial density, and established reimbursement pathways for advanced diagnostics and oncology drugs. The United States continues to shape evidence generation through precision oncology trials and regulatory pathways for orphan and breakthrough therapies, while Canada contributes through neuro-oncology networks and publicly funded cancer care, although provincial reimbursement timelines can influence access.

Europe benefits from coordinated research under European Union frameworks, strong neurosurgery and radiotherapy infrastructure in Germany, France, Italy, Spain, and the United Kingdom, and EMA pathways for orphan and advanced therapies. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia increase oncology trial participation, genomic testing capacity, advanced imaging adoption, and local biopharma investment. Latin America is seeing rising demand through major referral centers in Brazil and Mexico, but affordability, molecular diagnostic access, and timely radiotherapy availability remain constraints. The Middle East is strengthening tertiary oncology care through GCC health-system investment, international clinical partnerships, and specialty hospital expansion, while Africa faces the greatest infrastructure gaps in MRI access, neurosurgical capacity, pathology services, and high-cost therapy availability, making workforce development and diagnostic capacity building essential.

Key Group Insights for Global Neuro-Oncology Growth

Within the G7, the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom anchor much of the global clinical evidence base for brain tumor therapeutics through mature oncology systems, academic trial networks, advanced imaging infrastructure, and regulatory experience with orphan drugs. NATO economies overlap with many of these strengths, especially in advanced imaging, cybersecurity for health data, biomanufacturing resilience, and cross-institutional research collaboration.

The European Union is important for harmonized regulatory science, cross-border research, health technology assessment, and rare cancer collaboration, particularly where multi-country evidence is needed for small neuro-oncology populations. BRICS countries are increasingly relevant because of large patient populations, expanding domestic pharmaceutical capabilities, growing genomic medicine programs, and broader access initiatives in tertiary oncology centers. ASEAN markets are strengthening specialty oncology infrastructure through referral hospitals, private health investment, and regional clinical collaboration, while GCC countries are expanding high-acuity cancer care, molecular diagnostics, and medical tourism capabilities; however, access across both groups often depends on reimbursement reform, trained neuro-oncology teams, and availability of molecular diagnostics.

Key Country Insights in Brain Tumor Therapeutics

The United States leads in venture funding, FDA oncology approvals, precision diagnostics, academic trial enrollment, and adoption of advanced neuroimaging, while Canada offers strong population-based cancer registries, organized care pathways, and publicly funded access frameworks. Mexico and Brazil are important Latin American markets where tertiary centers are advancing neurosurgery, radiotherapy, and neuro-oncology services, but affordability, molecular testing coverage, and uneven regional access remain key constraints.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist neurosurgery, radiotherapy capacity, molecular pathology, and clinical research activity, with Germany and France particularly strong in hospital-based oncology infrastructure and the United Kingdom supported by national cancer research networks. Russia maintains major oncology centers and neurosurgical expertise, but access and supply-chain complexity can affect availability of advanced therapies and diagnostics. China is scaling domestic innovation, genomic testing, and oncology trial activity; India has high unmet need and expanding private oncology infrastructure, though access varies widely by region and payer type; Japan emphasizes regulatory rigor, elderly patient care, and high-quality diagnostics; South Korea is strong in digital health, imaging technology, and oncology research; and Australia contributes through high-quality clinical trials, rare cancer networks, and coordinated specialist care despite geographic access challenges.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-defined development strategies, including IDH mutation, MGMT methylation, TERT promoter, EGFR alteration, BRAF mutation, NTRK fusion, H3 K27 alteration, and 1p/19q codeletion status where clinically relevant. Early alignment between therapeutic programs, companion diagnostics, tissue requirements, liquid biopsy feasibility, and MRI-based response criteria can reduce development risk.

Organizations should also invest in blood-brain barrier delivery science, rational combination strategies with radiotherapy and immunotherapy, equitable trial recruitment, pediatric and adult evidence planning where appropriate, and real-world evidence systems. Partnerships with academic neuro-oncology centers, imaging core labs, patient advocacy groups, regulators, and payers can improve enrollment, evidence quality, patient access, and launch readiness without relying on speculative market assumptions.

Research Methodology

This executive summary is based on triangulation of publicly available clinical, regulatory, epidemiological, and scientific sources, including IARC GLOBOCAN cancer statistics, WHO CNS tumor classification updates, FDA and EMA public records, peer-reviewed neuro-oncology literature, clinical trial registries, treatment guidelines, and health technology assessment materials.

The research approach emphasizes verified evidence over speculative market claims. Insights were assessed through disease burden, treatment standards, pipeline direction, biomarker adoption, regional care infrastructure, reimbursement context, regulatory activity, and technology readiness, with particular attention to data consistency, source credibility, and clinical relevance for brain tumor therapeutics.

Conclusion: Precision, Access, and Evidence Will Define Leadership

Brain tumor therapeutics remain one of oncology's most challenging segments because aggressive biology, tumor heterogeneity, immune suppression, and the blood-brain barrier limit treatment durability. Even so, the field is advancing through molecular diagnosis, targeted therapy, improved imaging, precision radiotherapy, tumor treating fields, and smarter clinical trial models.

The organizations best positioned for sustainable leadership will combine rigorous science with practical access strategies. Stakeholders that validate differentiated mechanisms, integrate AI responsibly, prove clinically meaningful outcomes, expand diagnostic readiness, and collaborate across global neuro-oncology ecosystems can help improve survival, preserve neurological function, and enhance quality of life for patients with brain tumors.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Brain Tumor Therapeutics Market, by Product Type

• 7.1. Devices
  • 7.1.1. Imaging Equipment
  • 7.1.2. Radiation Equipment
  • 7.1.3. Surgical Instruments
• 7.2. Medicine

8. Brain Tumor Therapeutics Market, by Therapeutic Approach

• 8.1. Chemotherapy
  • 8.1.1. Alkylating Agents
  • 8.1.2. Antimetabolites
  • 8.1.3. Plant Alkaloids
• 8.2. Immunotherapy
  • 8.2.1. CAR T
  • 8.2.2. Checkpoint Inhibitors
  • 8.2.3. Vaccines
• 8.3. Radiotherapy
  • 8.3.1. Brachytherapy
  • 8.3.2. External Beam Radiotherapy
  • 8.3.3. Stereotactic Radiosurgery
• 8.4. Surgery
  • 8.4.1. Craniotomy
  • 8.4.2. Stereotactic Surgery

9. Brain Tumor Therapeutics Market, by Tumor Type

• 9.1. Astrocytoma
• 9.2. Glioblastoma
• 9.3. Meningioma

10. Brain Tumor Therapeutics Market, by Distribution Channel

• 10.1. Hospital Pharmacies
• 10.2. Online Pharmacies
• 10.3. Retail Pharmacies

11. Brain Tumor Therapeutics Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Brain Tumor Therapeutics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Brain Tumor Therapeutics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Brain Tumor Therapeutics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc.
• 16.2. AIVITA Biomedical, Inc.
• 16.3. Amgen Inc.
• 16.4. AstraZeneca PLC
• 16.5. Bayer AG
• 16.6. Bio-Rad Laboratories, Inc.
• 16.7. Bristol-Myers Squibb Company
• 16.8. CNS Pharmaceuticals, Inc.
• 16.9. Curtana Pharmaceuticals
• 16.10. Dr. Reddy's Laboratories Ltd.
• 16.11. Eisai Inc.
• 16.12. Eli Lilly and Company
• 16.13. F. Hoffmann-La Roche AG
• 16.14. GE HealthCare Technologies Inc.
• 16.15. Gentech, Inc.
• 16.16. GlaxoSmithKline PLC
• 16.17. Illumina, Inc.
• 16.18. Johnson & Johnson Services, Inc.
• 16.19. Merck KGaA
• 16.20. Novartis AG
• 16.21. Novocure GmbH
• 16.22. Pfizer Inc.
• 16.23. Qiagen N.V.
• 16.24. Sanofi S.A.
• 16.25. Siemens Healthcare GmbH
• 16.26. Y-mAbs Therapeutics, Inc.